Skip to main content
SpringerLink
Log in

Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

In a number of countries, the prevalence of neonatal opioid withdrawal syndrome (NOWS) is increasing. While NOWS is ultimately the result of opioid exposure in utero, a wide range of risk factors have been associated with the prevalence of NOWS, extending beyond just drug exposure. This article reviews the available literature on factors associated with the incidence of NOWS in opioid-exposed neonates. A range of risk factors have been associated with NOWS, including features of neonatal drug exposure, maternal and neonatal characteristics, aspects of labor and delivery, and genetics. Increased length of gestation and higher birth weight were consistently associated with an increased risk of NOWS, while breast feeding and ‘rooming-in’ were associated with a reduced risk of NOWS. Additionally, several genetic factors have also been associated with NOWS severity. There is conflicting evidence on the association between NOWS and other risk factors including opioid dose, neonate sex, and the use of some medications during pregnancy. This may be in part attributable to differences in how NOWS is diagnosed and the variety of methodologies across studies. While a large number of risk factors associated with NOWS are non-modifiable, encouraging pregnant women to reduce other drug use (including smoking), breast feed their child, and the judicious use of medications during pregnancy may help reduce the prevalence of NOWS. The presence or absence of NOWS in an opioid-exposed neonate is associated with a wide range of factors. Some of these modifiable risk factors may be potential targets for the primary prevention of NOWS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Finnegan LP, Connaughton JF, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2:141–58.

    CAS  PubMed  Google Scholar 

  2. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015;35:650–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Filteau J, Coo H, Dow K. Trends in incidence of neonatal abstinence syndrome in Canada and associated healthcare resource utilization. Drug Alcohol Depend. 2018;185:313–21.

    PubMed  Google Scholar 

  4. Uebel H, Wright IM, Burns L, et al. Epidemiological evidence for a decreasing incidence of neonatal abstinence syndrome, 2000–11. Paediatr Perinat Epidemiol. 2016;30:267–73.

    PubMed  Google Scholar 

  5. Davies H, Gilbert R, Johnson K, et al. Neonatal drug withdrawal syndrome: cross-country comparison using hospital administrative data in England, the USA, Western Australia and Ontario, Canada. Arch Dis Child Fetal Neonatal Ed. 2016;101:26–30.

    Google Scholar 

  6. Winkelman TNA, Villapiano N, Kozhimannil KB, Davis MM, Patrick SW. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004–2014. Pediatrics. 2018;141:e20173520.

    PubMed  PubMed Central  Google Scholar 

  7. Villapiano NLG, Winkelman TNA, Kozhimannil KB, Davis MM, Patrick SW. Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013 rural and urban differences in neonatal abstinence syndrome letters. JAMA Pediatr. 2017;171:194–6.

    PubMed  Google Scholar 

  8. Falk J, Dahl M, Raymond CB, et al. Opioid use during pregnancy: a population-based cohort study. CMAJ Open. 2017;5:E517–23.

    PubMed  PubMed Central  Google Scholar 

  9. Kuczyńska K, Grzonkowski P, Kacprzak Ł, Zawilska JB. Abuse of fentanyl: an emerging problem to face. Forensic Sci Int. 2018;289:207–14.

    PubMed  Google Scholar 

  10. Corr TE, Hollenbeak CS. The economic burden of neonatal abstinence syndrome in the United States. Addiction. 2017;112:1590–9.

    PubMed  Google Scholar 

  11. Reynolds F. Placental transfer of opioids. Baillière Clin Anaesthesiol. 1987;1:859–81.

    Google Scholar 

  12. Wachman EM, Farrer LA. The genetics and epigenetics of neonatal abstinence syndrome. Semin Fetal Neonatal Med. 2019;24:105–10.

    PubMed  Google Scholar 

  13. Bhavsar R, Kushnir A, Kemble N. Incidence and severity of neonatal abstinence syndrome in infants with prenatal exposure to methadone versus buprenorphine. Pediatrics. 2018;142(1 MeetingAbstract):145.

    Google Scholar 

  14. Heimann K, Bartz C, Silvestri A, Merz U, Hornchen H, Kentrup H. Methadone substitution during pregnancy. Relationship between dose and effect in neonatal abstinence syndrome. Geburtshilfe Frauenheilkd. 2006;66:277–83.

    CAS  Google Scholar 

  15. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9:81–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction. 2012;107:53–62.

    PubMed  PubMed Central  Google Scholar 

  18. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol. 2014;180:673–86.

    PubMed  Google Scholar 

  19. Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ. Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. Pharmacotherapy. 2017;37:824–39.

    CAS  PubMed  Google Scholar 

  20. Mullins N, Galvin SL, Ramage M, et al. Buprenorphine and naloxone versus buprenorphine for opioid use disorder in pregnancy: a cohort study. J Addict Med. 2019 Sep 17. [Epub ahead of print].

  21. Cleary BJ, Donnelly J, Strawbridge J, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction. 2010;105:2071–84.

    PubMed  Google Scholar 

  22. de Castro A, Jones HE, Johnson RE, Gray TR, Shakleya DM, Huestis MA. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin Chem. 2011;57:449–58.

    PubMed  PubMed Central  Google Scholar 

  23. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153–93.

    CAS  PubMed  Google Scholar 

  24. Shiu JR, Ensom MH. Dosing and monitoring of methadone in pregnancy: literature review. Can J Hosp Pharm. 2012;65:380–6.

    PubMed  PubMed Central  Google Scholar 

  25. Sanlorenzo LA, Stark AR, Patrick SW. Neonatal abstinence syndrome: an update. Curr Opin Pediatr. 2018;30:182–6.

    PubMed  PubMed Central  Google Scholar 

  26. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116:665–71.

    CAS  PubMed  Google Scholar 

  27. Swortfiguer D, Cissoko H, Giraudeau B, Jonville-Bera AP, Bensouda L. Autret-Leca E [Neonatal consequences of benzodiazepines used during the last month of pregnancy]. Arch Pediatr. 2005;12:1327–31.

    CAS  PubMed  Google Scholar 

  28. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol. 2008;199(396):e1–7.

    Google Scholar 

  29. Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ. 2017;358:j3326.

    PubMed  PubMed Central  Google Scholar 

  30. Scully M, Geoghegan N, Corcoran P, Tiernan M, Keenan E. Specialized drug liaison midwife services for pregnant opioid dependent women in Dublin. Ireland. J Subst Abuse Treat. 2004;26:27–33.

    Google Scholar 

  31. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci. 2008;45:107–13.

    PubMed  Google Scholar 

  32. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. JAMA Pediatr. 2006;160:173–6.

    Google Scholar 

  33. Kaltenbach K, Holbrook AM, Coyle MG, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction. 2012;107:45–52.

    PubMed  PubMed Central  Google Scholar 

  34. Pierog S, Chandavasu O, Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J Pediatr. 1977;90:630–3.

    CAS  PubMed  Google Scholar 

  35. Robe LB, Gromisch DS, Iosub S. Symptoms of neonatal ethanol withdrawal. Curr Alcohol. 1981;8:485–93.

    CAS  PubMed  Google Scholar 

  36. Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol. 2011;204(139):e1–9.

    Google Scholar 

  37. Kreitinger C, Gutierrez H, Hamidovic A, et al. The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment. J Matern Fetal Neonatal Med. 2016;29:783–8.

    CAS  PubMed  Google Scholar 

  38. Fulroth R, Phillips B, Durand DJ. Perinatal outcome of infants exposed to cocaine and/or heroin in utero. Am J Dis Child. 1989;143:905–10.

    CAS  PubMed  Google Scholar 

  39. O’Connor AB, Kelly BK, O’Brien LM. Maternal and infant outcomes following third trimester exposure to marijuana in opioid dependent pregnant women maintained on buprenorphine. Drug Alcohol Depend. 2017;180:200–3.

    PubMed  Google Scholar 

  40. Kelly L, Dooley J, Cromarty H, et al. Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications. Can Fam Physician. 2011;57:e441–7.

    PubMed  PubMed Central  Google Scholar 

  41. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69–78.

    CAS  PubMed  Google Scholar 

  42. Stewart RD, Nelson DB, Adhikari EH, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013;209(267):e1–5.

    Google Scholar 

  43. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat. 2003;24:363–7.

    PubMed  Google Scholar 

  44. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92:854–8.

    CAS  PubMed  Google Scholar 

  45. Lund IO, Fitzsimons H, Tuten M, Chisolm MS, O’Grady KE, Jones HE. Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse Rehabil. 2012;3:17–25.

    PubMed  PubMed Central  Google Scholar 

  46. Haabrekke KJ, Slinning K, Walhovd KB, Wentzel-Larsen T, Moe V. The perinatal outcome of children born to women with substance dependence detoxified in residential treatment during pregnancy. J Addict Dis. 2014;33:114–23.

    PubMed  Google Scholar 

  47. Walhovd KB, Bjørnebekk A, Haabrekke K, et al. Child neuroanatomical, neurocognitive, and visual acuity outcomes with maternal opioid and polysubstance detoxification. Pediatr Neurol. 2015;52(326–32):e3.

    Google Scholar 

  48. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119:1070–6.

  49. Terplan M, Laird HJ, Hand DJ, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018;131:803–14.

    PubMed  PubMed Central  Google Scholar 

  50. Jansson LM, Dipietro JA, Elko A, Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med. 2007;20:677–85.

    CAS  PubMed  Google Scholar 

  51. Wachman EM, Hunter RG, Shrestha H, et al. Maternal hair cortisol levels as a novel predictor of neonatal abstinence syndrome severity: a pilot feasibility study. Dev Psychobiol. 2019 Jul 24. [Epub ahead of print].

  52. Rose-Jacobs R, Trevino-Talbot M, Lloyd-Travaglini C, et al. Could prenatal food insecurity influence neonatal abstinence syndrome severity? Addiction. 2019;114:337–43.

    PubMed  Google Scholar 

  53. Tarasuk VS. Household food insecurity with hunger is associated with women’s food intakes, health and household circumstances. J Nutr. 2001;131:2670–6.

    CAS  PubMed  Google Scholar 

  54. Desai RJ, Huybrechts KF, Hernandez-Diaz S, et al. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ. 2015;350:h2102.

    PubMed  PubMed Central  Google Scholar 

  55. O’Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics. 2009;123:e614–21.

    PubMed  Google Scholar 

  56. Burns L, Mattick RP. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug Alcohol Rev. 2007;26:487–92.

    PubMed  Google Scholar 

  57. Liu AJ, Jones MP, Murray H, Cook CM, Nanan R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol. 2010;50:253–8.

    PubMed  Google Scholar 

  58. Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome: a national prospective study. Eur Addict Res. 2009;15:128–34.

    PubMed  Google Scholar 

  59. Hagopian GS, Wolfe HM, Sokol RJ, Ager JW, Wardell JN, Cepeda EE. Neonatal outcome following methadone exposure in utero. J Matern Fetal Med. 1996;5:348–54.

    CAS  PubMed  Google Scholar 

  60. Jansson LM, Velez ML, McConnell K, et al. Maternal buprenorphine treatment and infant outcome. Drug Alcohol Depend. 2017;180:56–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Shirel T, Hubler CP, Shah R, et al. Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease. Am J Hematol. 2016;91:416–9.

    CAS  PubMed  Google Scholar 

  62. Charles MK, Cooper WO, Jansson LM, Dudley J, Slaughter JC, Patrick SW. Male sex associated with increased risk of neonatal abstinence syndrome. Hosp Pediatr. 2017;7:328–34.

    PubMed  PubMed Central  Google Scholar 

  63. Jansson LM, DiPietro JA, Elko A, Velez M. Infant autonomic functioning and neonatal abstinence syndrome. Drug Alcohol Depend. 2010;109:198–204.

    PubMed  PubMed Central  Google Scholar 

  64. Unger A, Jagsch R, Bäwert A, et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? Gend Med. 2011;8:355–64.

    PubMed  PubMed Central  Google Scholar 

  65. Holbrook A, Kaltenbach K. Gender and NAS: does sex matter? Drug Alcohol Depend. 2010;112:156–9.

    PubMed  Google Scholar 

  66. Yen E, Kaneko-Tarui T, Ruthazer R, Harvey-Wilkes K, Hassaneen M, Maron JL. Sex-dependent gene expression in infants with neonatal opioid withdrawal syndrome. J Pediatr. 2019;214(60–5):e2.

    Google Scholar 

  67. DiPietro JA, Voegtline KM. The gestational foundation of sex differences in development and vulnerability. Neuroscience. 2017;342:4–20.

    CAS  PubMed  Google Scholar 

  68. Ruwanpathirana R, Abdel-Latif ME, Burns L, et al. Prematurity reduces the severity and need for treatment of neonatal abstinence syndrome. Acta Paediatr. 2015;104:e188–94.

    CAS  PubMed  Google Scholar 

  69. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985;233:1–6.

    CAS  PubMed  Google Scholar 

  70. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991;118:933–7.

    CAS  PubMed  Google Scholar 

  71. Lemon LS, Naimi A, Caritis SN, Platt RW, Venkataramanan R, Bodnar LM. The role of preterm birth in the association between opioid maintenance therapy and neonatal abstinence syndrome. Paediatr Perinatal Epidemiol. 2018;32:213–22.

    Google Scholar 

  72. Kuschel CA, Austerberry L, Cornwell M, Couch R, Rowley RSH. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed. 2004;89:F390–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr. 1976;88:1044–8.

    CAS  PubMed  Google Scholar 

  74. Moore JN, Gastonguay MR, Ng CM, et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clin Pharmacol Ther. 2018;103:1029–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Mack G, Thomas D, Giles W, Buchanan N. Methadone levels and neonatal withdrawal. J Paediatr Child Health. 1991;27:96–100.

    CAS  PubMed  Google Scholar 

  76. Pritham UA. Breastfeeding promotion for management of neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs. 2013;42:517–26.

    PubMed  Google Scholar 

  77. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013;102:1060–6.

    CAS  PubMed  Google Scholar 

  78. Isemann B, Meinzen-Derr J, Akinbi H. Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol. 2011;31:25–9.

    CAS  PubMed  Google Scholar 

  79. McQueen KA, Murphy-Oikonen J, Gerlach K, Montelpare W. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care. 2011;11:282–90.

    PubMed  Google Scholar 

  80. Yonke N, Maston R, Weitzen S, Leeman L. Breastfeeding intention compared with breastfeeding postpartum among women receiving medication-assisted treatment. J Hum Lact. 2019;35:71–9.

    PubMed  Google Scholar 

  81. MacMillan KDL, Rendon CP, Verma K, Riblet N, Washer DB, Volpe Holmes A. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatr. 2018;172:345–51.

    PubMed  PubMed Central  Google Scholar 

  82. Abrahams RR, Kelly SA, Payne S, Thiessen PN, Mackintosh J, Janssen PA. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician. 2007;53:1722–30.

    PubMed  PubMed Central  Google Scholar 

  83. Holmes AV, Atwood EC, Whalen B, et al. Rooming-into treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics. 2016;137:e20152929.

    PubMed  Google Scholar 

  84. McKnight S, Coo H, Davies G, et al. Rooming-in for infants at risk of neonatal abstinence syndrome. Am J Perinatol. 2016;33:495–501.

    PubMed  Google Scholar 

  85. Wachman EM, Hayes MJ, Sherva R, et al. Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend. 2015;155:253–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Wachman EM, Hayes MJ, Brown MS, et al. Association of oprm1 and comt single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013;309:1821–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Xuei X, Flury-Wetherill L, Almasy L, et al. Human genetics study: association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence. Addict Biol. 2008;13:80–7.

    CAS  PubMed  Google Scholar 

  88. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol. 2011;77:33–9.

    CAS  PubMed  Google Scholar 

  89. Hosák L. Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry. 2007;22:276–81.

    PubMed  Google Scholar 

  90. Wachman EM, Hayes MJ, Shrestha H, et al. Epigenetic variation in OPRM1 gene in opioid-exposed mother-infant dyads. Genes Brain Behav. 2018;17:e12476.

    CAS  PubMed  Google Scholar 

  91. Schempf AH, Strobino DM. Drug use and limited prenatal care: an examination of responsible barriers. Am J Obstet Gynecol. 2009;200(412):e1–10.

    Google Scholar 

  92. Garg M, Garrison L, Leeman L, et al. Validity of self-reported drug use information among pregnant women. Matern Child Health J. 2016;20:41–7.

    PubMed  PubMed Central  Google Scholar 

  93. Patrick SW, Schumacher RE, Horbar JD, et al. Improving care for neonatal abstinence syndrome. Pediatrics. 2016;137(5):e20153835.

    PubMed  PubMed Central  Google Scholar 

  94. Miles J, Sugumar K, Macrory F, Sims DG, D’Souza SW. Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants. Child Care Health Dev. 2007;33:206–12.

    CAS  PubMed  Google Scholar 

  95. Cleveland LM, Gill SL. “Try not to judge”: mothers of substance exposed infants. MCN Am J Matern Child Nurs. 2013;38:200–5.

    PubMed  Google Scholar 

  96. Dave CV, Goodin A, Zhu Y, et al. Prevalence of maternal-risk factors related to neonatal abstinence syndrome in a commercial claims database: 2011–2015. Pharmacotherapy. 2019;39(10):1005–11.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The School of Population and Global Health, The University of Western Australia, Crawley, WA, Australia

    Erin Kelty & David B. Preen

Authors
  1. Erin Kelty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David B. Preen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erin Kelty.

Ethics declarations

Funding

No funding was used to assist in the preparation of this article.

Conflict of interest

Erin Kelty and David B. Preen have no conflicts of interest that are directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kelty, E., Preen, D.B. Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review. CNS Drugs 33, 1113–1120 (2019). https://doi.org/10.1007/s40263-019-00681-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-019-00681-9

Search

Navigation